Re:Search - Details

Bioaffinity Mass Spectrometry

SUBMISSION ID 2601

Contact Details

Provider Eskitis Institute - Eskitis
Partnership Hub Coordinator Name BIO Ventures for Global Health
221 Main Street, Suite 1600
San Francisco, CA 94105
USA
Tel: +1 415 446 94 43
partnershiphub@bvgh.org

Submission Summary

TitleBioaffinity Mass Spectrometry
Executive Summary/Abstract Eskitis has established a mass spectrometry-based medium-throughput screening platform capable of identifying compounds binding to proteins, delivering drug leads and potential pathways to crystallisation and structure-based design. Proteins can be analysed in their folded, native state without labelling.
Keywords screening; natural product; spectrometry; protein; extract; fraction; mass;

Disease Selection

Disease Rabies;Trachoma;Schistosomiasis;Malaria;Buruli Ulcer;Tuberculosis;Human African trypanosomiasis;Endemic treponematoses (Yaws);Soil transmitted helminthiasis;Onchocerciasis;Dengue/dengue hemorrhagic fever;Lymphatic filariasis;Leprosy;Leishmaniasis;Chagas disease (American trypanosomiasis);Foodborne trematode infections (Clonorchiasis, Fascioliasis, Opistorchiasis, Paragonimiasis);Snakebite;Echinococcosis;Podoconiosis;Cysticercosis;Dracunculiasis (guinea-worm disease)
Comment
Name(s) of Infectious Organism(s)
Vector(s)
Human Target Organ(s)
Mechanism of Action (MoA)
Molecular or Cellular Target Name(s)

Type of Data

Type of Data Enabling Technology Platform







ENABLING TECHNOLOGY PLATFORM DATA

Technology/Platform Description

 
Name of Platform Bioaffinity Mass Spectrometry
Summary/Abstract Text Eskitis has established a mass spectrometry-based medium-throughput screening platform capable of identifying compounds binding to proteins, delivering drug leads and potential pathways to crystallisation and structure-based design. Proteins can be analysed in their folded, native state without labelling.
Keywords extract; mass; protein; spectrometry; natural product; fraction; screening
References Vu, H. et al 2008 . Journal of Biomolecular Screening 13 4 , 265–275. Maresca, A. et al 2009 . Journal of the American Chemical Society 131 8 , 3057–3062.

Technology Benefits for Disease

 
Field(s) of Current Application tuberculosis; Malaria
How to use the Technology Platform for Disease This platform is available to find compounds that bind directly to unlabelled proteins form the proteomes of NTD vectors.
Potential Benefits for Disease Application This platform is available to find compounds that bind directly to unlabelled proteins form the proteomes of NTD vectors.
List of Current Users Australian Research Council; Seattle Biomedical Research Institute; University of Washington; Bill Melinda Gates Foundation

Alternative technology/platforms

 
Name of Competitive Technology/Platform(s)

Publication Status

 
Publicly Available Data (Reference) Vu, H. et al 2008 . Journal of Biomolecular Screening 13 4 , 265–275. Maresca, A. et al 2009 . Journal of the American Chemical Society 131 8 , 3057–3062.

Technology Patent Status

 
Proprietary Platform No

Collaboration StatusD

 
In house only No
Names of
Partners Australian Research Council
Service Providers
Academic Centers University of Washington
Public Private Partnerships Seattle Biomedical Research Institute
Funding Agencies Bill Melinda Gates Foundation
Other Collaborators

 

WIPO Re:Search

Technical Advisor to WIPO